Skip to content

Development Plan for Evorpacept

We are pursuing a robust development plan for evorpacept across a breadth of indications in solid and hematologic cancers with multiple combination partners.

Modality/
Target 		Program Indication
Phase
 Status
Evorpacept Programs
Anti-cancer Antibodies
ASPEN-06
Evorpacept, Herceptin®, CYRAMZA® + Paclitaxel¹
2L or 3L Advanced HER2-Overexpressing Gastric/Gastro­esophageal Junction (GEJ)
end of phase 2
Next steps pending FDA input
ASPEN-Breast
Evorpacept, Herceptin®+ chemotherapy
Enhertu®-Experienced HER2-Positive Breast Cancer
beginning of phase 2
Launching Q1 ‘25, FPI mid-year ’25
ASPEN-CRC
Evorpacept, Erbitux®+ chemotherapy
2L, EGFR-Naïve Metastatic Colorectal Cancer (CRC)
end of phase 1
Launching Q1 ‘25, FPI mid-year ’25
Zanidatamab + Evorpacept³
HER2-Expressing Breast Cancer and Other Cancers
end of phase 1
Data presented at SABCS ‘24
Sarclisa® + Dexamethasone⁵ + Evorpacept
RRMM (Relapsed or Refractory Multiple Myeloma)
beginning of phase 1
FPI Q3 ‘24, Currently Enrolling
Checkpoint Inhibitors
ASPEN-03
Evorpacept + KEYTRUDA®²
1L PD-L1 Positive Advanced HNSCC (Head and Neck Squamous Cell Carcinoma)
middle of phase 2
Topline results Q2 ‘25
ASPEN-04
Evorpacept, KEYTRUDA®, 5FU + Platinum²
1L Advanced HNSCC
middle of phase 2
Topline results Q2 ‘25
ADCs
ASPEN-07
Evorpacept + PADCEV®
Urothelial Cancer
mid/end of phase 1
Data update Q2’ 25
Enhertu® (I-SPY)4 + Evorpacept
HER2-positive Breast Cancer and Metastatic Breast Cancer
mid/end of phase 1
Currently Enrolling
ALX2004 Program
ADC
Single-agent dose-escalation and expansion
EFGR-Expressing Solid Tumors
Filing IND Q1 '25

ALX2004 Program

Single-agent dose-escalation and expansion
Modality/Target
ADC
Indication
EFGR-Expressing Solid Tumors
Status
Filing IND Q1 '25
Explore Our Clinical Trials

ALX Oncology retains worldwide rights to evorpacept.

  1. Lilly supplies CYRAMZA® for ALX Oncology’s ASPEN-06 program
  2. Merck supplies KEYTRUDA® for ALX Oncology’s ASPEN-03 and ASPEN-04 programs
  3. Jazz Pharmaceuticals sponsors zanidatamab clinical trial
  4. Quantum Leap Healthcare Collaborative sponsors I-SPY clinical trial
  5. Sanofi sponsors Sarclisa clinical trial